<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03764735</url>
  </required_header>
  <id_info>
    <org_study_id>18-110-0004</org_study_id>
    <nct_id>NCT03764735</nct_id>
  </id_info>
  <brief_title>Study of SkQ1 as Treatment for Dry-eye Syndrome</brief_title>
  <acronym>VISTA-1</acronym>
  <official_title>A Phase 3, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of SkQ1 Ophthalmic Solution for the Treatment of Dry Eye Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitotech, SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ORA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mitotech, SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether SkQ1 ophthalmic solutions are safe and&#xD;
      effective compared to placebo for the treatment of the signs and symptoms of dry eye&#xD;
      syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multi-center, double-masked, randomized, placebo-controlled study comprising 5 visits over&#xD;
      the course of approximately 9 weeks. Qualified subjects are randomized 1:1:1 to receive&#xD;
      either High Dose SkQ1 ophthalmic solution, Low Dose SkQ1 ophthalmic solution, or Placebo&#xD;
      (vehicle of SkQ1 ophthalmic solution).&#xD;
&#xD;
      The Primary Endpoints are:&#xD;
&#xD;
      Change from Baseline (Visit 2) to Visit 5 in Corneal Fluorescein Staining;&#xD;
&#xD;
      Change from Baseline (Visit 2) to Visit 5 in Grittiness Symptom&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 27, 2018</start_date>
  <completion_date type="Actual">February 9, 2019</completion_date>
  <primary_completion_date type="Actual">February 9, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel-group study of two strengths of ophthalmic solution versus placebo solution</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Central Corneal Staining change from baseline</measure>
    <time_frame>From baseline to Day 57</time_frame>
    <description>Change of Corneal Fluorescein Staining</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Grittiness change from baseline</measure>
    <time_frame>From baseline to Day 57</time_frame>
    <description>Change of patient-reported grittiness</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Corneal and conjunctival staining</measure>
    <time_frame>Through Day 57</time_frame>
    <description>Corneal and conjunctival fluorescein staining on a 0-4 point scale in all regions through Day 57 and following exposure to a controlled adverse environment (CAEÂ®) on Day 57 only. Regions: central, superior, inferior, temporal, nasal, corneal sum, conjunctival sum and total</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lissamine green staining</measure>
    <time_frame>Through Day 57</time_frame>
    <description>Lissamine green staining in all regions Scale; regions: central, superior, inferior, temporal, nasal, corneal sum, and total</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Schirmer's Test</measure>
    <time_frame>Through Day 57</time_frame>
    <description>Unanesthetized Schirmer's Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Discomfort and 4-symptom Questionaire</measure>
    <time_frame>Through Day 57</time_frame>
    <description>Ocular Discomfort &amp; 4-Symptom Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OSDI</measure>
    <time_frame>Through Day 57</time_frame>
    <description>Ocular Surface Disease Index (OSDI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Discomfort</measure>
    <time_frame>Through Day 57</time_frame>
    <description>Ocular Discomfort Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom Diary</measure>
    <time_frame>Through Day 57</time_frame>
    <description>Subject Symptom Daily Diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tear Film Breakup Time</measure>
    <time_frame>Through Day 57</time_frame>
    <description>Tear Film Breakup Time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conjunctival Redness</measure>
    <time_frame>Through Day 57</time_frame>
    <description>Conjunctival Redness Scale Conjunctival Redness Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lid Margin Redness</measure>
    <time_frame>Through Day 57</time_frame>
    <description>Lid Margin Redness Scale</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">451</enrollment>
  <condition>Dry Eye Syndrome</condition>
  <arm_group>
    <arm_group_label>SkQ1 Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>SkQ1 (Vehicle)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose - SkQ1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low-dose ophthalmic solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose - SkQ1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High-dose ophthalmic solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low Dose - SkQ1</intervention_name>
    <description>SkQ1 Low dose ophthalmic solution</description>
    <arm_group_label>Low Dose - SkQ1</arm_group_label>
    <other_name>Vizomitin(R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High dose - SkQ1</intervention_name>
    <description>SkQ1 High Dose ophthalmic solution</description>
    <arm_group_label>High Dose - SkQ1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SkQ1 (Vehicle)</intervention_name>
    <description>Vehicle for SkQ1 ophthalmic solution</description>
    <arm_group_label>SkQ1 Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be at least 18 years of age;&#xD;
&#xD;
          -  Provide written informed consent;&#xD;
&#xD;
          -  Have a subject reported history of dry eye;&#xD;
&#xD;
          -  Have a history of use of eye drops for dry eye symptoms ;&#xD;
&#xD;
          -  Ocular Discomfort;&#xD;
&#xD;
          -  Schirmer's Test score;&#xD;
&#xD;
          -  Have corneal fluorescein staining ;&#xD;
&#xD;
          -  Have lissamine green conjunctival Staining ;&#xD;
&#xD;
          -  Have a conjunctival redness;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have participated in the previous SkQ1 ophthalmic solution Phase 2 treatment study;&#xD;
&#xD;
          -  Have any clinically significant slit lamp findings at Visit 1;&#xD;
&#xD;
          -  Be diagnosed with an ongoing ocular infection or active ocular inflammation at Visit&#xD;
             1;&#xD;
&#xD;
          -  Have had any ocular and/or lid surgeries within 6 months of Visit 1 or any planned&#xD;
             over the study period;&#xD;
&#xD;
          -  Have an uncontrolled systemic disease;&#xD;
&#xD;
          -  Be a woman who is pregnant, nursing or planning a pregnancy;&#xD;
&#xD;
          -  Be a woman of childbearing potential who is not using an acceptable means of birth&#xD;
             control;&#xD;
&#xD;
          -  Have a known allergy and/or sensitivity to the study drug or its components ;&#xD;
&#xD;
          -  Have a condition or be in a situation which the investigator feels may put the subject&#xD;
             at significant risk, may confound the study results, or may interfere significantly&#xD;
             with the subject's participation in the study;&#xD;
&#xD;
          -  Be currently enrolled in an investigational drug or device study or have used an&#xD;
             investigational drug or device within 30 days of Visit 1;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lawrence T Friedhoff, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Mitotech, SA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cornea &amp; Cataract Consultants of Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Research Foundation</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Care Insititute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Maine Eye Care</name>
      <address>
        <city>Lewiston</city>
        <state>Maine</state>
        <zip>04240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andover Eye Associates</name>
      <address>
        <city>Andover</city>
        <state>Massachusetts</state>
        <zip>01810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vita Eye Clinic</name>
      <address>
        <city>Shelby</city>
        <state>North Carolina</state>
        <zip>28150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Total Eye Care, PA</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 30, 2018</study_first_submitted>
  <study_first_submitted_qc>December 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 5, 2018</study_first_posted>
  <last_update_submitted>November 19, 2019</last_update_submitted>
  <last_update_submitted_qc>November 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dry Eye</keyword>
  <keyword>Dry Eye Syndrome</keyword>
  <keyword>SkQ1</keyword>
  <keyword>KCS</keyword>
  <keyword>Keratoconjunctivitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

